SAFETY AND IMMUNOGENICITY OF PALIVIZUMAB (SYNAGIS) ADMINISTERED FOR TWO SEASONS


    loading  Checking for direct PDF access through Ovid

Abstract

To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.

    loading  Loading Related Articles